ResearchOur PeopleAllison Naleway

Allison L. Naleway, PhD

Meet Allison Naleway

Allison Naleway was interested in science from a young age, but it was a coincidental suggestion from a visiting professor that led her to choose a career in epidemiology. Her research portfolio includes studies of the flu vaccine, the HPV vaccine, and vaccination during pregnancy.

Allison Naleway, PhD, is a distinguished investigator whose research focuses on the evaluation of vaccine safety and effectiveness and on the surveillance of vaccine-preventable or other infectious diseases.

Dr. Naleway is an investigator with the Vaccine Safety Datalink, a national project of the Centers for Disease Control and Prevention (CDC) that links electronic medical record data from several integrated health care delivery organizations to monitor vaccine safety. Additionally, she has collaborated with the CDC on studies to assess the effectiveness of COVID-19 and influenza vaccination during pregnancy and in health care personnel. She has also evaluated the effects of human papillomavirus vaccination on HPV-related outcomes.

Dr. Naleway received her master’s and doctoral degrees in epidemiology from The University of Iowa’s College of Public Health and completed a postdoctoral fellowship in epidemiology at the Marshfield Clinic Research Foundation. She has an adjunct faculty appointment with The University of Iowa College of Public Health’s Department of Epidemiology. She joined CHR in 2003.

Selected Current Studies

  • Vaccine Safety Datalink-Infrastructure Activities—VSD (CDC)
  • Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel— RECOVER (CDC)
  • Prospective Cohort Study of COVID-19 Vaccine Effectiveness in Children and Adults—CASCADIA: (CDC)
  • Virtual Influenza and COVID-19 Surveillance and Vaccines Effectiveness Network—VISION (CDC)

Selected Publications

  • Naleway AL, Grant L, Caban-Martinez AJ, Wesley MG, Burgess JL, Groover K, Gaglani M, Yoon SK, Tyner HL, Meece J, Kuntz JL, Yoo YM, Schaefer-Solle N, Olsho LEW, Gerald JK, Rose S, Thiese MS, Lundgren J, Groom HC, Mak J, Louzado Feliciano P, Edwards LJ, Lutrick K, Dunnigan K, Phillips AL, Lamberte JM, Noriega R, Sokol BE, Odean M, Ellingson KD, Smith M, Hegmann KT, Respet K, Dickerson M, Cruz A, Fleary DE, Murthy K, Hunt A, Azziz-Baumgartner E, Gallimore-Wilson D, Harder JA, Odame-Bamfo L, Viergutz J, Arvay M, Jones JM, Mistry P, Thompson MG, Fowlkes AL. Incidence of SARS-CoV-2 infection among COVID-19 vaccinated and unvaccinated healthcare personnel, first responders, and other essential and frontline workers: Eight US locations, January-September 2021. Influenza Other Respir Viruses. 2022 Jan 13. doi: 10.1111/irv.12956. Epub ahead of print. PMID: 35023288.
  • Irving SA, Ball SW, Booth SM, Regan AK, Naleway AL, Buchan SA, Katz MA, Effler PV, Svenson LW, Kwong JC, Feldman BS, Klein NP, Chung H, Simmonds K; PREVENT study team. A multi-country investigation of influenza vaccine coverage in pregnant individuals, 2010-2016. Vaccine. 2021 Nov 18:S0264-410X(21)01463-8. doi: 10.1016/j.vaccine.2021.11.018. Epub ahead of print. PMID: 34802789.
  • Naleway AL, Groom HC, Crawford PM, Salas SB, Henninger ML, Donald JL, Smith N, Thompson MG, Blanton LH, Bozio CH, Azziz-Baumgartner E. Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID-19 Among Persons Aged ≥12 Years, by COVID-19 Vaccination Status - Oregon and Washington, July 4-September 25, 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 19;70(46):1608-1612. doi: 10.15585/mmwr.mm7046a4. PMID: 34793417; PMCID: PMC8601415.
  • Embi PJ, Levy ME, Naleway AL, Patel P, Gaglani M, Natarajan K, Dascomb K, Ong TC, Klein NP, Liao IC, Grannis SJ, Han J, Stenehjem E, Dunne MM, Lewis N, Irving SA, Rao S, McEvoy C, Bozio CH, Murthy K, Dixon BE, Grisel N, Yang DH, Goddard K, Kharbanda AB, Reynolds S, Raiyani C, Fadel WF, Arndorfer J, Rowley EA, Fireman B, Ferdinands J, Valvi NR, Ball SW, Zerbo O, Griggs EP, Mitchell PK, Porter RM, Kiduko SA, Blanton L, Zhuang Y, Steffens A, Reese SE, Olson N, Williams J, Dickerson M, McMorrow M, Schrag SJ, Verani JR, Fry AM, Azziz-Baumgartner E, Barron MA, Thompson MG, DeSilva MB. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1553-1559. doi: 10.15585/mmwr.mm7044e3. PMID: 34735426; PMCID: PMC8568092.
  • Naleway AL, Crane B, Irving SA, Bachman D, Vesco KK, Daley MF, Getahun D, Glenn SC, Hambidge SJ, Jackson LA, Klein NP, McCarthy NL, McClure DL, Panagiotakopoulos L, Panozzo CA, Vazquez-Benitez G, Weintraub ES, Zerbo O, Kharbanda EO. Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. Ther Adv Drug Saf. 2021 Jun 14;12:20420986211021233. doi: 10.1177/20420986211021233. PMID: 34178302; PMCID: PMC8207278.
  • Naleway AL, Weinmann S, Krishnarajah S, Arondekar B, Fernandez J, Swamy G, Myers E. Pregnancy after treatment for cervical cancer precursor lesions in a retrospective matched cohort. PLOS One. 2015;10:e0117525.
  • Naleway AL, Weinmann S, Crane B, Gee J, Markowitz LE, Dunne EF. Evaluation of a surveillance case definition for anogenital warts, Kaiser Permanente Northwest. Sex Transm Dis. 2014;41:496-500.
  • Naleway AL, Irving SA, Henninger ML, Li D, Shifflett P, Ball S, Williams J, Cragan J, Gee J, Thompson MG. Safety of influenza vaccination during pregnancy: a review of subsequent maternal obstetric events and findings from two recent cohort studies. Vaccine. 2014;32:3122-7. Epub 2014 Apr 14.
  • Naleway AL, Henkle EM, Ball S, Bozeman S, Gaglani MJ, Kennedy ED, Thompson MG. Barriers and facilitators to influenza vaccination and vaccine coverage in a cohort of healthcare personnel. Am J Infect Control. 2014;42:371-5.
  • Naleway AL, Gold R, Drew L, Riedlinger K, Henninger ML, Gee J. Reported adverse events in young women following quadrivalent human papillomavirus vaccination. J Womens Health. 2012;21:425-35. Epub 2012 Jan 9.

Follow Us